Mucosa-associated Lymphoid Tissue Lymphoma
📧 Sign up to get email alerts when something new happens for Mucosa-associated Lymphoid Tissue Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma [Phase 2]
Phase 2 trial evaluating Orelabrutinib followed by response-adapted ultra-low-dose 4 Gy radiation as first-line therapy for mucosa-associate…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) [Phase 2]
Phase 2 trial evaluating frontline zanubrutinib plus rituximab for mucosa-associated lymphoid tissue lymphoma (MALT) is recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating an all-oral combination of clarithromycin and lenalidomide for relapsed or refractory mucosa-associated lymphoid ti…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma [Phase 3]
A Phase 3 randomized trial comparing chlorambucil alone, chlorambucil with rituximab, and rituximab alone in MALT lymphoma has been complete…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue [Phase 2]
Phase 2 trial results for rituximab plus lenalidomide in mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) have been reported.
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicu…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS research · 2016-12-08Clinical Trial Update: Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma
A prospective study evaluating first-line Helicobacter pylori eradication for early-stage extragastric mucosa-associated lymphoid tissue lym…
-
CLINICAL_TRIALS trial_result · 2015-03-30Clinical Trial Update: VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy [Phase 2]
Phase 2 trial of Velcade (bortezomib) in mucosa-associated lymphoid tissue lymphoma pretreated with multiple prior systemic therapies has be…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of fludarabine and rituximab for marginal zone non-Hodgkin's lymphoma (MALT lymphoma) and has c…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction [Phase 1]
This Phase 1 trial evaluated bortezomib in patients with advanced cancer and kidney dysfunction. The study has completed.
-
CLINICAL_TRIALS research · 2010-09-28Clinical Trial Update: Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type [Phase 2]
Phase 2 clinical trial evaluating lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma; current trial status is unknown.
-
CLINICAL_TRIALS trial_result · 2009-07-22Clinical Trial Update: VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy [Phase 2]
A phase 2 trial of Velcade (bortezomib) in mucosa-associated lymphoid tissue lymphoma patients pretreated with prior systemic therapy has co…
-
CLINICAL_TRIALS trial_result · 2009-06-18Clinical Trial Update: Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients [Phase 2]
A Phase 2 clinical trial evaluating Thalidomide for mucosa-associated lymphoid tissue lymphoma has completed.